Neoadjuvant radiotherapy concurrent with weekly paclitaxel and carboplatin and followed by surgery in locally advanced non-small-cell lung cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 26, Issue 2, 2003, Pages 184-187

  Kuten, Abraham ^a,b   Anacak, Y ^a   Abdah Bortnyak, R ^a   Chetver, L ^a   Zen Al Deen, I ^c   Daoud, K ^c   Nijem, R ^c   Billan, S ^a   Best, L ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c Italian Hospital of Haifa   (Israel)

Author keywords

Carboplatin; Concurrent chemoradiotherapy; Paclitaxel

Indexed keywords

CARBOPLATIN; DOCETAXEL; PACLITAXEL;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INFUSION; DRUG RESPONSE; ESOPHAGITIS; FEMALE; HUMAN; LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MALE; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; SURGICAL MORTALITY; SURVIVAL TIME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PNEUMONECTOMY; RADIOTHERAPY DOSAGE; REMISSION INDUCTION; SURVIVAL ANALYSIS;

EID: 0037391177     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200304000-00017     Document Type: Article

References (27)

1. Vokes EE, Mauer AM, Hoffman PC, et al. Paclitaxel/carboplatin plus ifosfamide in non-small cell lung cancer. Semin Oncol 1997;24(suppl 12):S12-67-9.
2. Choy H, Safran H. Preliminary analysis of a phase II study of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Semin Oncol 1995;22(suppl 9):55-7.
3. Kelly K, Pan Z, Murphy J, et al. A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer. Clin Cancer Res 1997;3:1117-23.
4. Kosmidis P, Mylonakis N, Skarlos D, et al. Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol 2000;11:799-805.
5. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
6. Jassem J. Combined chemotherapy and radiation in locally advanced non-small-cell lung cancer. Lancet Oncol 2001;2:335-42.
7. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-9.
8. Morsac B, Scott C, Curran W, et al. A quality-adjusted time without symptoms and toxicity (QTWIST) analysis of Radiotherapy Oncology Group (RTOG) [Abstract]. Proc Am Soc Clin Oncol 2000;20:313a.
9. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19:3210-8.
10. Akerley W, Choy H. Single-agent paclitaxel and radiation for non-small cell lung cancer. Semin Radiat Oncol 1999;9(suppl 1):85-9.
11. Clamon G, Herndon J, Cooper R, et al. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 1999;17:4-11.
12. Choy H, MacRae R. The current state of paclitaxel and radiation in the combined-modality therapy of non-small cell lung cancer. Semin Oncol 2001;28(suppl 14):17-22.
13. Belani CP. Interim analysis of a phase II study of induction weekly paclitaxel/carboplatin regimens followed by maintenance weekly paclitaxel for advanced and metastatic non-small cell lung cancer. Semin Oncol 2001;28(suppl 14):14-6.
14. Hainsworth JD, Urba WJ, Hon JK, et al. One-hour paclitaxel plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicentre, phase II trial. Eur J Cancer 1998;34:654-8.
15. Natale RB. Preliminary results of a phase I/II clinical trial of paclitaxel and carboplatin in non-small cell lung cancer. Semin Oncol 1996;23(suppl 16):51-4.
16. Johnson DH, Paul DM, Hande KR, et al. Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN-46). Semin Oncol 1996;23(suppl 16):42-6.
17. Langer CJ, Millenson M, O'Dwyer P, et al. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network. Semin Oncol 1996;23(suppl 16):35-41.
18. Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995;13:1860-70.
19. Johnson DH, Paul DM, Hande KR, et al. Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 1996;14:2054-60.
20. Belani CP, Aisner J, Bahri S, et al. Chemoradiotherapy in non-small cell lung cancer: paclitaxel/carboplatin/radiotherapy in regionally advanced disease. Semin Oncol 1996;23(suppl 16):113-6.
21. Langer CJ. Concurrent chemoradiation using paclitaxel and carboplatin in locally advanced non-small cell lung cancer. Semin Radiat Oncol 1999;9(suppl 1):108-16.
22. Socinski MA, Rosenman JG, Halle J, et al. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trial. Cancer 2001;92:1213-23.
23. Choy H, Devore RF 3rd, Hande KR, et al. A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study). Int J Radiat Oncol Biol Phys 2000;47:931-7.
24. Lau D, Leigh B, Gandara D, et al. Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial. J Clin Oncol 2001;19:442-7.
25. Ratanatharathorn V, Lorvidhaya V, Maoleekoonpairoj S, et al. Phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. Lung Cancer 2001;31:257-65.
26. Bonomi P, Siddiqui S, Lincoln S, et al. Escalating paclitaxel doses combined with carboplatin/etoposide and thoracic radiotherapy as preoperative or definitive treatment for stage III non-small cell lung cancer. Semin Oncol 1996;23(suppl 16):102-7.
27. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.